Effects of SA13353, a transient receptor potential vanilloid 1 agonist, on leukocyte infiltration in lipopolysaccharide-induced acute lung injury and ovalbumin-induced allergic airway inflammation

Journal of Pharmacological Sciences

Volumn 112, Issue 4, 2010, Pages 487-490

  Tsuji, Fumio ^a   Murai, Masaaki ^a   Oki, Kenji ^a   Inoue, Hiroyuki ^a   Sasano, Minoru ^a   Tanaka, Hiroyuki ^b   Inagaki, Naoki ^b   Aono, Hiroyuki ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Lung inflammation; SA13353; Transient receptor potential vanilloid 1

Indexed keywords

CAPSAICIN; DEXAMETHASONE; INTERLEUKIN 12P40; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; OVALBUMIN; PREDNISOLONE; SA 13353; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR AGONIST;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EOSINOPHIL COUNT; FEMALE; LEWIS RAT; LYMPHOCYTE COUNT; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; RAT;

EID: 77951218847     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09295SC     Document Type: Article

References (15)

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
2. Van Der Stelt M, Di Marzo V. Endovanilloids: putative endoge-nous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem. 2004;271:1827-1834.
3. Caterina MJ, Julius D. The vanilloid receptor: a molecular gate-way to the pain pathology. Annu Rev Neurosci. 2001;24:487-517.
4. Geppetti P, Materazzi S, Nicoletti P. The transient receptor potential vanilloid 1: Role in airway inflammation and disease. Eur J Pharmacol. 2006;533:207-214.
5. Murai M, Tsuji F, Nose M, Seki I, Oki K, Setoguchi C, et al. SA13353(1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl) propyl]urea) inhibits TNF-α production through the activation of capsaicin-sensitive afferent neurons mediated via transient recep-tor potential vanilloid 1 in vivo. Eur J Pharmacol. 2008;588:309-315.
6. Ueda K, Tsuji F, Hirata T, Ueda K, Murai M, Aono H, et al. Preventive effect of SA13353 [1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea], a novel transient receptor potential vanilloid 1 agonist, on ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther. 2009;329:202-209.
7. Tsuji T, Murai M, Oki K, Seki I, Ueda K, Inoue H, et al. Transient receptor potential vanilloid 1 agonists as candidates for anti-in-flammatory and immunomodulatory agents. Eur J Pharmacol. 2010;627:332-339.
8. Iwamura H, Inushima K, Takeuchi K, Kakutani M, Wakitani K. Prophylactic effect of JTE-607 on LPS-induced acute lung injury in rats with CINC-1 inhibition. Inflamm Res. 2002;51:160-166.
9. Kato Y, Manabe T, Tanaka Y, Mochizuki H. Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia, and airway hyperresponsiveness in mice. J Immu-nol. 1999;162:7470-7479.
10. Petty TL. The acute respiratory distress syndrome: Evolution of concepts and progress. J Organ Dysfunct. 2006;2:5-14.
11. Nagai A. Pathology and pathophysiology of chronic obstructive pulmonary disease. Intern Med. 2002;41:265-269.
12. Bochner BS, Busse WW. Allergy and asthma. J Allergy Clin Immunol. 2005;115:953-959.
13. O'Byrne PM. Cytokines or their antagonists for the treatment of asthma. Chest. 2006;130:244-250.
14. Langrish CL, Chen Y, Blumenshein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201: 233-240.
15. Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int. 2008;57:121-134.